180 related articles for article (PubMed ID: 15160319)
21. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
22. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
24. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
25. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo T; Suzuki M
Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
[No Abstract] [Full Text] [Related]
26. [How to treat tumor-induced hypercalcemia].
Body JJ
Rev Prat; 2003 Dec; 53(19):2128-35. PubMed ID: 15008469
[TBL] [Abstract][Full Text] [Related]
27. Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD).
Pecherstorfer M; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):661-3. PubMed ID: 1450050
[No Abstract] [Full Text] [Related]
28. [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer].
Nishimura N; Matsushita Y; Takaoka K; Hashitani S; Noguchi K; Urade M
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2537-9. PubMed ID: 12506478
[TBL] [Abstract][Full Text] [Related]
29. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
30. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Wright JD; Tergas AI; Ananth CV; Burke WM; Hou JY; Chen L; Neugut AI; Richards CA; Hershman DL
Cancer Invest; 2015; 33(8):331-9. PubMed ID: 26068056
[TBL] [Abstract][Full Text] [Related]
31. [Two cases of stage IV breast cancer with severe hypercalcemia].
Ohsako T; Yamamoto Y; Kawazoe T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O; Sakamoto N; Iwase H
Gan To Kagaku Ryoho; 2006 Feb; 33(2):223-6. PubMed ID: 16484860
[TBL] [Abstract][Full Text] [Related]
32. [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Kusama M; Kaise H; Nakayama S; Ota D; Aoki T; Koyanagi Y; Matsunaga T; Nakamura Y
Gan To Kagaku Ryoho; 2000 May; 27(5):763-6. PubMed ID: 10832449
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates in breast cancer.
Mathew A; Brufsky A
Int J Cancer; 2015 Aug; 137(4):753-64. PubMed ID: 24824552
[TBL] [Abstract][Full Text] [Related]
35. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.
Lee DC; Lee GY
J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241
[TBL] [Abstract][Full Text] [Related]
36. Anterior uveitis complicating zoledronic acid infusion.
Colucci A; Modorati G; Miserocchi E; Di Matteo F; Rama P
Ocul Immunol Inflamm; 2009; 17(4):267-8. PubMed ID: 19657981
[TBL] [Abstract][Full Text] [Related]
37. Zoledronate.
Delmas PD
Br J Clin Pract Suppl; 1996 Sep; 87():15 discussion 22. PubMed ID: 8995012
[No Abstract] [Full Text] [Related]
38. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
39. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
40. Childhood cancer and hypercalcemia: report of a case treated with pamidronate.
Kutluk MT; Hazar V; Akyüz C; Varan A; Büyükpamukçu M
J Pediatr; 1997 May; 130(5):828-31. PubMed ID: 9152297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
